2126 — JW (Cayman) Therapeutics Co Share News
0.000.00%
Last trade - 00:00- HK$625.09m
- HK$347.70m
- CNY283.65m
Brief: JW (Cayman) Therapeutics Says NMPA Approved Supplemental New Drug Application For Relma-Cel
Brief: Jw Therapeutics Announces NMPA Approval Of Relmacabtagene Autoleucel Injection In Patients With Relapsed Or Refractory Follicular Lymphoma
Brief: Jw (Cayman) Therapeutics Noted Unusual Movements In Price & Trading Volume Of Shares Of Co On Stock Exchange
Brief: Jw (Cayman) Therapeutics Says Ind Approval From China's Nmpa For Clinical Trial Of Carteyva In Pediatric & Young Adult Patients
Brief: JW Therapeutics Announces IND Approval For The Clinical Trial Of Carteyva
Brief: Jw Therapeutics Announces Receipt Of Breakthrough Therapy Designation For Carteyva In Mantle Cell Lymphoma In China
Brief: JW (Cayman) Therapeutics Says It Got NMPA's IND Clearance For Pivotal Clinical Trial Of Carteyva
Brief: JW (Cayman) Therapeutics Posts FY Loss Of RMB702.3 Million
Brief: JW Therapeutics Announces NMPA Acceptance Of Supplemental New Drug Application For Carteyva In Patients With Follicular Lymphoma
Brief: JW (Cayman) Therapeutics Received Investigational New Drug Clearance From NMPA Of China For Clinical Trials
Brief: Temasek Holdings Private Limited's Long Position In JW Cayman Therapeutics Falls To 0% - HKEX Filing
Brief: JW (Cayman) Therapeutics Posts HY Loss RMB280.7 Mln Vs RMb650.0 Mln
Brief: Jw (Cayman) Therapeutics Updates On New Drug Application Of Relma-Cel In China
Brief: WuXi AppTec's Long Position In JW Cayman Therapeutics Falls To 3.80% - HKEX Filing
China's JW falls most in 4 months on shareholder stake sale plan report
Brief: Jw Cayman Therapeutics Announces Of Potential Substantial Shareholder Change
Brief: JW Cayman Therapeutics Posts FY Loss Attributable Of RMB1.66 Billion
Brief: Jw Cayman Therapeutics Has Been Included In Hong Kong Stock Connect List Under Shenzhen-Hong Kong Stock Connect
Brief: Goldman Sachs Group's Long Position In JW (Cayman) Therapeutics Increases To 5.28% - HKEX Filing